In March, the Department of Justice (DOJ) announced that a pilot program to incentivize individualized reporting was in development, which we reviewed here. True to its word, the DOJ's "Corporate Whistleblower Awards Pilot...more
8/12/2024
/ Corporate Misconduct ,
Corruption ,
Department of Justice (DOJ) ,
Enforcement Priorities ,
Federal Pilot Programs ,
Financial Crimes ,
Healthcare Fraud ,
Incentives ,
Pilot Programs ,
Public Corruption ,
Voluntary Disclosure ,
Whistleblower Awards ,
Whistleblowers ,
White Collar Crimes
The Department of Justice (DOJ) has made numerous recent public statements reflecting increased priorities for enforcement, especially in the health care industry. The DOJ has a variety of tools at its disposal to enforce...more
1/31/2022
/ Anti-Kickback Statute ,
Audits ,
Civil Investigation Demand ,
Cooperation ,
Criminal Investigations ,
Department of Justice (DOJ) ,
Enforcement Priorities ,
False Claims Act (FCA) ,
Government Investigations ,
Health Care Providers ,
Healthcare Fraud ,
Physicians ,
Voluntary Disclosure
The U.S. Department of Justice (DOJ) kicked off the new year by issuing two internal memoranda that are directly relevant to actions brought under the False Claims Act. The January 2018 memoranda offer valuable insight into...more
The U.S. Department of Justice (DOJ) kicked off the new year with two new resolutions to help clarify some enforcement and litigations policies, both of which are directly relevant to claims brought under the False Claims...more
A comprehensive understanding of the constantly evolving layers that make up federal anti-corruption statutes, sanctions regulations and export control restrictions is imperative for both the pharmaceutical and health care...more
6/16/2017
/ Anti-Corruption ,
AstraZeneca ,
Bribery ,
Bureau of Industry and Security (BIS) ,
Civil Monetary Penalty ,
Compliance ,
Corporate Misconduct ,
Cuba ,
Department of Justice (DOJ) ,
Economic Sanctions ,
Enforcement Actions ,
Export Administration Regulations (EAR) ,
Export Controls ,
Foreign Corrupt Practices Act (FCPA) ,
GlaxoSmithKline ,
Health Care Providers ,
Imports ,
Iran ,
Medical Devices ,
Novartis ,
Office of Foreign Assets Control (OFAC) ,
Open General Export Licences (OGELs) ,
Pharmaceutical Industry ,
Public Officials ,
Research and Development ,
Securities and Exchange Commission (SEC) ,
Settlement ,
Sudan ,
Teva Pharmaceuticals